

September 10, 2021

Sumitomo Dainippon Pharma Co., Ltd.

**Sumitomo Dainippon Pharma Announces Launch of TWYMEEG®
for the Treatment of Type 2 Diabetes in Japan**

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) announces today the launch of TWYMEEG® tablets 500mg (generic name: imeglimin hydrochloride, hereinafter, “this Drug”), for the treatment of type 2 diabetes in Japan on September 16, 2021. The launch of this Drug is the first in the world.

This Drug is an oral hypoglycaemic agent in a new chemical class of tetrahydrotriazine-containing molecules. It is thought that this Drug shows a glucose lowering effect by both a pancreatic action that promotes glucose concentration-dependent insulin secretion and an extra-pancreatic action that improves glucose metabolism in the liver and skeletal muscle (suppression of gluconeogenesis and improvement of glucose uptake) through an action on mitochondria. The clinical studies in Japan have confirmed the efficacy, safety, and tolerability of this Drug. This Drug has the potential to be a candidate for the treatment of type 2 diabetes in all stages of the current anti-diabetic treatment paradigm, including monotherapy or as an add-on to other glucose lowering therapies, including insulin.

Sumitomo Dainippon Pharma positions diabetes as one of its focus areas in the Japanese market, and currently commercializes several drugs for the treatment of type 2 diabetes, each with different mechanisms of action. The launch of this Drug allows us to offer yet another treatment option, thus making greater contributions to the treatment of type 2 diabetes.

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)